{"id":"lodoxamide","rwe":[],"tags":[{"label":"Mast Cell Stabilizer","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled receptor 35","category":"target"},{"label":"GPR35","category":"gene"},{"label":"S01GX05","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Solution/ Drops","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Vernal Keratitis","category":"indication"},{"label":"Vernal conjunctivitis","category":"indication"},{"label":"Vernal keratoconjunctivitis","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"specialPopulations":{"Pregnancy":"Because animal reproduction studies are not always predictive of human response, ALOMIDE(R) (lodoxamide tromethamine ophthalmic solution) 0.1% should be used during pregnancy only if clearly needed.","Geriatric use":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","Paediatric use":"Safety and effectiveness in pediatric patients below the age of years have not been established."}},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LODOXAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:02:34.999872+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lodoxamide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:02:41.909035+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:02:40.512013+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LODOXAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:02:40.823190+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201266/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:02:41.524813+00:00"}},"allNames":"alomide","offLabel":[],"synonyms":["lodoxamide","lodoxamide tromethamine","lodoxamide trometamol","alomide","U 42585E","U-42,585E"],"timeline":[{"date":"1993-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ALCON to Novartis"},{"date":"1993-09-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Alcon)"}],"aiSummary":"Alomide (LODOXAMIDE) is a small molecule mast cell stabilizer that targets G-protein coupled receptor 35. It was originally developed by ALCON and is currently owned by Novartis. Alomide is FDA-approved for the treatment of Vernal Keratitis, Vernal conjunctivitis, and Vernal keratoconjunctivitis. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As a result, its commercial status is uncertain.","approvals":[{"date":"1993-09-23","orphan":true,"company":"ALCON","regulator":"FDA"}],"brandName":"Alomide","ecosystem":[{"indication":"Vernal Keratitis","otherDrugs":[{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"}],"globalPrevalence":null},{"indication":"Vernal conjunctivitis","otherDrugs":[{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"}],"globalPrevalence":null},{"indication":"Vernal keratoconjunctivitis","otherDrugs":[{"name":"cromoglicic acid","slug":"cromoglicic-acid","company":"King Pharms"}],"globalPrevalence":1200000}],"mechanism":{"target":"G-protein coupled receptor 35","novelty":"Follow-on","targets":[{"gene":"GPR35","source":"DrugCentral","target":"G-protein coupled receptor 35","protein":"G-protein coupled receptor 35"}],"modality":"Small Molecule","drugClass":"Mast Cell Stabilizer","explanation":"","oneSentence":"","technicalDetail":"Alomide exerts its effects by selectively inhibiting the release of histamine and other mediators from mast cells, thereby reducing the symptoms of allergic eye conditions such as Vernal Keratitis, Vernal conjunctivitis, and Vernal keratoconjunctivitis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lodoxamide","title":"Lodoxamide","extract":"Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer. In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer."},"commercial":{"launchDate":"1993","_launchSource":"DrugCentral (FDA 1993-09-23, ALCON)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3325","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LODOXAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Lodoxamide","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:04:33.308183","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:43.105880+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cromoglicic acid","drugSlug":"cromoglicic-acid","fdaApproval":"1982-05-28","relationship":"same-class"},{"drugName":"levocabastine","drugSlug":"levocabastine","fdaApproval":"1993-11-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"nedocromil","drugSlug":"nedocromil","fdaApproval":"1992-12-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"emedastine","drugSlug":"emedastine","fdaApproval":"1997-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ketotifen","drugSlug":"ketotifen","fdaApproval":"1999-07-02","patentExpiry":"Mar 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"olopatadine","drugSlug":"olopatadine","fdaApproval":"1996-12-18","patentExpiry":"May 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"epinastine","drugSlug":"epinastine","fdaApproval":"2003-10-16","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"alcaftadine","drugSlug":"alcaftadine","fdaApproval":"2010-07-28","patentExpiry":"Mar 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cetirizine","drugSlug":"cetirizine","fdaApproval":"1995-12-08","patentExpiry":"Sep 15, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"lodoxamide","indications":{"approved":[{"name":"Vernal Keratitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"},{"name":"Vernal conjunctivitis","source":"DrugCentral","snomedId":318316003,"regulator":"FDA"},{"name":"Vernal keratoconjunctivitis","source":"DrugCentral","snomedId":317349009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1200000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2009[INST])"}],"offLabel":[{"name":"Allergic Keratoconjunctivitis","source":"DrugCentral","drugName":"LODOXAMIDE","evidenceCount":25,"evidenceLevel":"moderate"},{"name":"Allergic conjunctivitis","source":"DrugCentral","drugName":"LODOXAMIDE","evidenceCount":55,"evidenceLevel":"strong"},{"name":"Giant papillary conjunctivitis","source":"DrugCentral","drugName":"LODOXAMIDE","evidenceCount":55,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cromoglicic-acid","brandName":"cromoglicic acid","genericName":"cromoglicic acid","approvalYear":"1982","relationship":"same-class"},{"drugId":"levocabastine","brandName":"levocabastine","genericName":"levocabastine","approvalYear":"1993","relationship":"same-class"},{"drugId":"nedocromil","brandName":"nedocromil","genericName":"nedocromil","approvalYear":"1992","relationship":"same-class"},{"drugId":"emedastine","brandName":"emedastine","genericName":"emedastine","approvalYear":"1997","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"},{"drugId":"ketotifen","brandName":"ketotifen","genericName":"ketotifen","approvalYear":"1999","relationship":"same-class"},{"drugId":"olopatadine","brandName":"olopatadine","genericName":"olopatadine","approvalYear":"1996","relationship":"same-class"},{"drugId":"epinastine","brandName":"epinastine","genericName":"epinastine","approvalYear":"2003","relationship":"same-class"},{"drugId":"alcaftadine","brandName":"alcaftadine","genericName":"alcaftadine","approvalYear":"2010","relationship":"same-class"},{"drugId":"cetirizine","brandName":"cetirizine","genericName":"cetirizine","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution/ Drops","formulations":[{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"ALOMIDE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148358","MMSL":"1845","NDDF":"003991","UNII":"SPU695OD73","VUID":"4020849","CHEBI":"CHEBI:135333","VANDF":"4020837","INN_ID":"4351","RXNORM":"28859","UMLSCUI":"C0126120","chemblId":"CHEMBL1201266","ChEMBL_ID":"CHEMBL1201266","KEGG_DRUG":"D04762","DRUGBANK_ID":"DB06794","PDB_CHEM_ID":"WYB","PUBCHEM_CID":"44564","SNOMEDCT_US":"108859008","IUPHAR_LIGAND_ID":"9743","SECONDARY_CAS_RN":"63610-09-3","MESH_SUPPLEMENTAL_RECORD_UI":"C021702"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","company":"Alcon Laboratories, Inc.","brandName":"ALOMIDE","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1993-","companyName":"Alcon","relationship":"Original Developer"},{"period":"present","companyName":"Novartis","relationship":"Current Owner"}],"publicationCount":135,"therapeuticAreas":["Rare Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"S01GX05","allCodes":["S01GX05"]},"biosimilarFilings":[],"originalDeveloper":"Alcon","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"1993","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-09-23T00:00:00.000Z","mah":"ALCON","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:43.105880+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}